Denarda Dangaj

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


37 publications

En préparation
 
Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma
Barras David, Ghisoni Eleonora, Chiffelle Johanna, Orcurto Angela, Dagher Julien, Fahr Noémie, Benedetti Fabrizio, Crespo Isaac, Zimmermann Stefan, Duran Rafael et al., this Pre print is under peer review in Science Immunology.
[DOI][serval:BIB_097A733AD4EC]
Sous presse
 
Crosstalk of T cells within the ovarian cancer microenvironment.
Chap B.S., Rayroux N., Grimm A.J., Ghisoni E., Dangaj Laniti D. Trends in cancer. Peer-reviewed.
[DOI][Pmid][serval:BIB_40EBC2F4EC7B]
 
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.
Elewaut A., Estivill G., Bayerl F., Castillon L., Novatchkova M., Pottendorfer E., Hoffmann-Haas L., Schönlein M., Nguyen T.V., Lauss M. et al. Nature. Peer-reviewed.
[DOI][Pmid][serval:BIB_6B66C99B58FA]
 
Author Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_88A45E78E09C]
 
Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms.
Pétremand R., Chiffelle J., Bobisse S., Perez MAS, Schmidt J., Arnaud M., Barras D., Lozano-Rabella M., Genolet R., Sauvage C. et al. Nature biotechnology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF334A302D27]
2024
 
The Impact of Neoadjuvant Chemotherapy on Ovarian Cancer Tumor Microenvironment: A Systematic Review of the Literature.
Spagnol G., Ghisoni E., Morotti M., De Tommasi O., Marchetti M., Bigardi S., Tuninetti V., Tasca G., Noventa M., Saccardi C. et al., 2024/06/27. International journal of molecular sciences, 25 (13). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C1598EE7D8E]
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Lacher S.B., Dörr J., de Almeida G.P., Hönninger J., Bayerl F., Hirschberger A., Pedde A.M., Meiser P., Ramsauer L., Rudolph T.J. et al., 2024/05. Nature, 629 (8011) pp. 417-425. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_32E213209E57]
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Morotti M., Grimm A.J., Hope H.C., Arnaud M., Desbuisson M., Rayroux N., Barras D., Masid M., Murgues B., Chap B.S. et al., 2024/05. Nature, 629 (8011) pp. 426-434. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5FCB44D6E4AA]
 
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Barras D., Ghisoni E., Chiffelle J., Orcurto A., Dagher J., Fahr N., Benedetti F., Crespo I., Grimm A.J., Morotti M. et al., 2024/02/02. Science immunology, 9 (92) pp. eadg7995. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A58DD7E390E0]
2023
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
2022
 
Genetics and anatomy sculpt immune-cell partners of ovarian cancer
Dangaj Laniti Denarda, Coukos George, 2022/12/22. Nature, 612 (7941) pp. 634-636. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_01D5FAC4C129]
 
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.
Kandalaft L.E., Dangaj Laniti D., Coukos G., 2022/11. Nature reviews. Cancer, 22 (11) pp. 640-656. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B0D5013539C]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
2021
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J., Turrini R., Minasyan A., Barras D., Crespo I., Grimm A.J., Casado J., Genolet R., Benedetti F., Wicky A. et al., 2021/12/13. Cancer cell, 39 (12) pp. 1623-1642.e20. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4A546D8AF05A]
 
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E., Kosti P., Ronet C., Cribioli E., Rota G., Spill A., Reichenbach P., Zoete V., Dangaj Laniti D., Coukos G. et al., 2021/08. Journal for immunotherapy of cancer, 9 (8) pp. e002151. Peer-reviewed.
[DOI][Pmid][serval:BIB_3B098C62EF15]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Lanitis E., Rota G., Kosti P., Ronet C., Spill A., Seijo B., Romero P., Dangaj D., Coukos G., Irving M., 2021/02/01. The Journal of experimental medicine, 218 (2) pp. e20192203. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_75DE24FE756B]
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Baumgaertner P., Sankar M., Herrera F.G, Benedetti F., Barras D., Thierry A.C., Dangaj D., Kandalaft L.E., Coukos G., Xenarios I. et al., 2021. Frontiers in immunology, 12 p. 633910. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E707FFE34C52]
2020
 
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams S.F., Grimm A.J., Chiang C.L., Mookerjee A., Flies D., Jean S., McCann G.A., Michaux J., Pak H., Huber F. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e000875. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B7CF92C7BCB]
2019
 
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F. et al., 2019/06/10. Cancer cell, 35 (6) pp. 885-900.e10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95C8776874F3]
 
Tumor Landscapes: β-Catenin Drives Immune Desertification.
Dangaj D., Barras D., Coukos G., 2019/05/15. Clinical cancer research, 25 (10) pp. 2943-2945. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7529A1E77088]
2018
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBC10D090AEF]
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10AE95ADCEE8]
2017
 
Mechanisms regulating T-cell infiltration and activity in solid tumors.
Lanitis E., Dangaj D., Irving M., Coukos G., 2017/12/01. Annals of oncology, 28 (suppl_12) pp. xii18-xii32. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE2398AAD635]
2016
 
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith J.B., Lanitis E., Dangaj D., Buza E., Poussin M., Stashwick C., Scholler N., Powell D.J., 2016/11. Molecular therapy : the journal of the American Society of Gene Therapy, 24 (11) pp. 1987-1999. Peer-reviewed.
[DOI][Pmid][serval:BIB_EC7C7B783578]
 
Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.
Zsiros E., Dangaj D., June C.H., Kandalaft L.E., Coukos G., 2016. Oncoimmunology, 5 (5) pp. e1062210. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1852FDBECBFC]
2015
 
Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.
Dangaj D., Scholler N., 2015. Methods In Molecular Biology, 1319 pp. 37-49. Peer-reviewed.
[DOI][Pmid][serval:BIB_002FBB72C992]
Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.
Karapetsas A., Giannakakis A., Dangaj D., Lanitis E., Kynigopoulos S., Lambropoulou M., Tanyi J.L., Galanis A., Kakolyris S., Trypsianis G. et al., 2015. Biomed Research International, 2015 p. 712438. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_082FCA6C4652]
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.
Zsiros E., Duttagupta P., Dangaj D., Li H., Frank R., Garrabrant T., Hagemann I.S., Levine B.L., June C.H., Zhang L. et al., 2015. Clinical Cancer Research, 21 (12) pp. 2840-2850. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_87A4CCCAC4DE]
2014
 
Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.
Giannakakis A., Karapetsas A., Dangaj D., Lanitis E., Tanyi J., Coukos G., Sandaltzopoulos R., 2014. International Journal of Biochemistry and Cell Biology, 53 pp. 389-398.
[DOI][WoS][Pmid][serval:BIB_3EE5F8B4AE65]
2013
 
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D., Lanitis E., Zhao A., Joshi S., Cheng Y., Sandaltzopoulos R., Ra H.J., Danet-Desnoyers G., Powell D.J., Scholler N., 2013/08/01. Cancer research, 73 (15) pp. 4820-4829. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_74E16544B1E9]
Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.
Dangaj D., Scholler N., 2013. Oncoimmunology, 2 (8) pp. e25913. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B5DDB69A0181]
2012
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.
Lanitis E., Dangaj D., Hagemann I.S., Song D.G., Best A., Sandaltzopoulos R., Coukos G., Powell D.J., 2012. Plos One, 7 (11) pp. e49829.
[DOI][WoS][Pmid][serval:BIB_8DF38EB47D0C]
2011
 
Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.
Dangaj D., Abbott K.L., Mookerjee A., Zhao A., Kirby P.S., Sandaltzopoulos R., Powell D.J., Lamazière A., Siegel D.L., Wolf C. et al., 2011. PloS one, 6 (12) pp. e28386. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6DD161C4CAA4]
2008
Reactive oxygen species and HIF-1 signalling in cancer.
Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R., 2008/07/18. Cancer letters, 266 (1) pp. 12-20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A1D91B548B6]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University